Published Date: 08 Mar 2023
Results from the RESCUE BT2 trial showed that among patients with mild or major strokes, more patients taking tirofiban had better 90-day outcomes than aspirin.
Read Full News1.
Chemo causes lasting physical decline in breast cancer survivors
2.
No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma
3.
In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events
4.
Which women need more than mammograms for breast cancer screening?
5.
Cancer research in the US is world class. With the government pulling out, its future is uncertain
1.
Hemophilia Beyond Boundaries: Unconventional Therapies in Bleeding Disorder Care
2.
Can AI Become Our Oncologic Ally? A Look at Artificial Intelligence in Cancer Detection and Control
3.
Prevention of Thrombotic Complications in High-Risk Patients
4.
Neoadjuvant Radiotherapy & Endocrine Therapy in ER+ Breast Cancer Treatment
5.
Personalized Survivorship Navigation in Precision Cancer Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
2.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
5.
Case-Based Learning: Oncology
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation